Patents by Inventor Christopher P. Alvares

Christopher P. Alvares has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Coding sequences of the human BRCA1 gene
    Patent number: 6838256
    Abstract: isolated coding sequences and to the protein sequences they code for. This invention is directed to three coding sequence of the BRCA1 gene. The three coding sequences, BRCA1(omi1), BRCA1(omi2), and BRCA1(omi3) and their frequencies of occurrence are provided together with the protein sequences they code for. Another aspect of this invention is a method of determining the consensus sequence for any gene. Another aspect of the invention is a method of identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because they have inherited a causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with any of the isolated BRCA1 coding sequences.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: January 4, 2005
    Assignee: Gene Logic Inc.
    Inventors: Patricia D. Murphy, Antonette C. Allen, Christopher P. Alvares, Brenda S. Critz, Sheri J. Olson, Denise B. Schelter, Bin Zeng
  • Coding sequences of the human BRCA1 gene
    Publication number: 20030022184
    Abstract: This invention is directed to the isolated coding sequences and to the protein sequences they code for. This invention is directed to three coding sequence of the BRCA1 gene. The three coding sequences, BRCA1(omi1), BRCA1(omi2), and BRCA1(omi3) and their frequencies of occurrence are provided together with the protein sequences they code for. Another aspect of this invention is a method of determining the consensus sequence for any gene. Another aspect of the invention is a method of identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because they have inherited a causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with any of the isolated BRCA1 coding sequences. This invention is further related to protein therapy with BRCA1(omi) proteins or their functional equivalent.
    Type: Application
    Filed: October 22, 2001
    Publication date: January 30, 2003
    Applicant: OncorMed. Inc.
    Inventors: Patricia D. Murphy, Antonette C.P. Allen, Christopher P. Alvares, Brenda S. Critz, Sheri J. Olson, Denise Thurber, Bin Zeng
  • Coding sequences of the human BRCA1 gene
    Publication number: 20020183268
    Abstract: Isolated coding sequences and to the protein sequences they code for. This invention is directed to three coding sequence of the BRCA1 gene. The three coding sequences, BRCA1(omi1), BRCA1(omi2), and BRCA1(omi3) and their frequencies of occurrence are provided together with the protein sequences they code for. Another aspect of this invention is a method of determining the consensus sequence for any gene. Another aspect of the invention is a method of identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because they have inherited a causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with any of the isolated BRCA1 coding sequences.
    Type: Application
    Filed: December 13, 2000
    Publication date: December 5, 2002
    Inventors: Patricia D. Murphy, Antonette C. Allen, Christopher P. Alvares, Brenda S. Critz, Sheri J. Olson, Denise B. Schelter, Bin Zeng
  • Coding sequences of the human BRCA1 gene
    Patent number: 6130322
    Abstract: This invention is directed to the isolated coding sequences and to the protein sequences they code for. This invention is directed to three coding sequence of the BRCA1 gene. The three coding sequences, BRCA1.sup.(omi1), BRCA1.sup.(omi2), and BRCA1.sup.(omi3) and their frequencies of occurrence are provided together with the protein sequences they code for. Another aspect of this invention is a method of determining the consensus sequence for any gene. Another aspect of the invention is a method of identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because they have inherited a causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with any of the isolated BRCA1 coding sequences. This invention is further related to protein therapy with BRCA.sup.(omi) proteins or their functional equivalent.
    Type: Grant
    Filed: May 6, 1998
    Date of Patent: October 10, 2000
    Assignee: Gene Logic, Inc.
    Inventors: Patricia D. Murphy, Antonette C. P. Allen, Christopher P. Alvares, Brenda S. Critz, Sheri J. Olson, Denise Thurber, Bin Zeng
  • Coding sequences of the human BRCA1 gene
    Patent number: 5750400
    Abstract: This invention is directed to three coding sequences of the BRCA1 gene. The three coding sequences, BRCA1.sup.(omi1), BRCA1.sup.(omi2) and BRCA1.sup.(omi3) as well as their frequencies of occurrence are provided together with the protein sequences they code for. Another aspect of this invention is a method of determining the consensus sequence for any gene. Another aspect of the invention is a method of identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because they have inherited a causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with any of the isolated BRCA1 coding sequences.
    Type: Grant
    Filed: February 12, 1997
    Date of Patent: May 12, 1998
    Assignee: OncorMed, Inc.
    Inventors: Patricia D. Murphy, Antonette C. Allen, Christopher P. Alvares, Brenda S. Critz, Sheri J. Olson, Denise B. Schelter, Bin Zeng
  • Consensus sequence of the human BRCA1 gene
    Patent number: 5654155
    Abstract: A consensus DNA sequence has been determined for the BRCA1 gene. As has been seven polymorphic sites and their rates of occurrence in normal BRCA1 genes. The consensus gene BRCA1.sup.(omi) and the seven polymorphic sites will provide greater accuracy and reliability for genetic testing. One skilled in the art will be better able to avoid misinterpretations of changes in the gene, determine the presence of a normal gene, and of mutations, and to classify tumors.
    Type: Grant
    Filed: February 12, 1996
    Date of Patent: August 5, 1997
    Assignee: OncorMed, Inc.
    Inventors: Patricia D. Murphy, Antonette C. Allen, Christopher P. Alvares, Brenda S. Critz, Sheri J. Olson, Denise B. Schelter, Bin Zeng